Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate‐to‐severe psoriasis after 1 year of treatment: Real‐world practice

Abstract

There are no studies which directly compare efficacy in Psoriasis Area and Severity Index (PASI) response of secukinumab and ixekizumab. The main aim of this study was to compare the efficacy and safety of both drugs used to treat moderate‐to‐severe psoriasis patients over 52 weeks. Secondary objectives were to identify which factors related to prior biologic treatment influenced their efficacy and analyze data obtained at 12 weeks. A retrospective observational study was carried out, in which a group of the first 59 patients treated with secukinumab after its commercialization, was compared with another group of the first 29 patients treated with ixekizumab. The PASI 75, 90, and 100 response obtained at 52 weeks was 64.4%, 49.2%, and 41.4% for secukinumab and 75.9%, 62.1%, and 41.4% for ixekizumab, respectively, with no statistically significant differences. Regarding previous biological treatment, both treatments showed a decrease in efficacy as the number of prior biologics increases. No differences were found between secukinumab and ixekizumab in bio‐naïve or bio‐experienced patients, with the exception of a higher PASI 75 response at week 52 for ixekizumab in those patients with two or more previous biologics (P = .039) Secukinumab and ixekizumab have demonstrated high efficacy and safety, with no statistically significant differences.

Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database

“…This study characterizes adults with moderate-to-severe psoriasis initiating one of the three biologics of interest in routine clinical practice. The median age of patients was 51-52 years, and most patients were 45-64 years of age, similar to published reports [20,25]. The majority of patients were white, as aligned with the 2010 National Health and Nutrition Examination Survey findings, which demonstrated higher prevalence of psoriasis in Caucasians [26].…”

“…In a real-world study conducted in the USA, nearly 60% of patients with moderate-to-severe psoriasis who were on biologic therapy were prescribed concomitant topical corticosteroids [22]; systemic corticosteroids were the most common nonbiologic systemic therapy, with about one-quarter of patients having prior use, followed closely by methotrexate, which is consistent with a recent real-world study [20]. Similar to prior reports, previous exposure to biologic therapies was also high across all treatment cohorts, at around 50% [25,30]. In one study, comparison of realworld treatment patterns among psoriasis patients treated with ixekizumab or adalimumab revealed a higher rate of prior use of biologics in ixekizumab users compared with adalimumab users (65.8% versus 35.8%) [20].…”

“…This study describes the characteristics of psoriasis patients initiating treatment with three biologics: guselkumab, secukinumab, or ixekizumab in the USA. Although previous realworld studies have explored treatment patterns among this patient population [19,20,22,24,25], this study describes patients across all three treatment cohorts, leveraging a dermatology-specific EMR platform, which provides comprehensive clinical information including disease severity measures and BMI, captured at the point-of-care by dermatology providers.…”

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months

“…The current findings of favorable treatment patterns among biologic-experienced IXE users compared to SEC users are consistent with findings from clinical trials and other real-world studies examining clinical outcomes [24][25][26]. A real-world study comparing clinical outcomes between IXE and SEC patients with psoriasis who have two or more previous biologic therapies demonstrated a significantly higher PASI 75 (75% improvement in PASI) response among IXE-treated than SEC-treated patients at week 52 (IXE 100% vs. SEC 54.5%; p = 0.039) [25]. Likewise, indirect comparison using network meta-analysis showed that IXE users had higher PASI 90 response rate than SEC (72.1% vs. 67.0%) during 48-52 weeks of treatment [26].…”

Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease

“…These are specialized helper T-cells producing IL-17 and thereby influencing the NF-kβ pathway, and have been implicated in the pathogenesis of a variety of autoimmune diseases. IL-17 antagonists (e.g., Secukinumab and Ixekizumab) are commercially available and FDA approved for the treatment of ankylosing spondylitis and psoriatic arthritis, and may represent potential agents for LGLL, especially in the setting of association with autoimmune disorders [79][80][81][82][83] (Figure 2).…”